SECURE Registry
Help evaluate the long-term safety of CIMZIA (certolizumab pegol) when used in normal clinical practice in patients with Crohn's disease as compared to patients taking other Crohn's disease medications by registering your patients in the SECURE Registry. Your contribution to the SECURE Registry will provide future patients and physicians with the knowledge necessary to make meaningful treatment decisions.
http://registry.praintl.com/portal/page/portal/registry/SECURE

Crohn's & Me
Help your patients make a connection with other people who have Crohn's disease (CD). Crohn's & Me offers disease information, support, and resources created for patients, their friends, and families. The site also features inspirational stories of real patients who have learned how they can live their lives to the fullest despite their disease.
http://www.crohnsandme.com/

The Foundation for Clinical Research in Inflammatory Bowel Disease
The Foundation Web site offers information about inflammatory bowel diseases, including CD.
http://www.myibd.org/

Equal Employment Opportunity Commission
The US Equal Employment Opportunity Commission is a government agency that protects people from employment discrimination, including discrimination based on race, color, religion, sex, national origin, and disability. You may also call the EEOC at 1-800-669-4000.
http://www.eeoc.gov/

Americans With Disabilities Act Web Site
Learn about what "reasonable accommodations" may be afforded to your patients in the workplace, such as frequent bathroom breaks or sick days.
http://www.ada.gov/

The Crohn's and Colitis Foundation of America
The Crohn's and Colitis Foundation of America (CCFA) is dedicated to finding a cure for CD and ulcerative colitis, and to improving the lives of those affected by the diseases. The CCFA supports and offers education, research, and scientific information. You may also call the CCFA at 1-800-932-2423.
http://www.ccfa.org/

American College of Gastroenterology
The American College of Gastroenterology (ACG) is a leading professional and educational organization for gastroenterologists in the United States. Visit their site to learn about educational opportunities and register for the annual meeting, which will take place October 28-November 2, 2011 in Washington, DC.
http://www.acg.gi.org/

Digestive Disease Week
Digestive Disease Week (DDW) is the world's largest gathering of physicians and researchers in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery. Learn more about this year's meeting, which takes place May 7–June 10, 2011 in Chicago.
http://www.ddw.org/wmspage.cfm?parm1=679

UCB Customer Service and Medical Information
1-800-477-7877
For customer service, press option 7
For medical information, press option 9

Clinical Literature About CIMZIA

  1. Feagan BG, Coteur G, Tan, S, Keininger DL, Schreiber S. Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease. Am J Gastroenterol. 2009;104(8):1976-1983.
  2. Feagan BG, Reilly MC, Gerlier L, Brabant Y, Brown M, Schreiber S. Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE 2 study. Aliment Pharmacol Ther. 2010;31(12):1276-1285.
  3. Goel N and Stephens S. Mini-review: certolizumab pegol. mAbs. 2010;2(2):137-147.
  4. Hanauer SB, Panes J, Colombel JF, Bloomfield R, Schreiber S, Sandborn WJ. Clinical trial: impact of prior infliximab therapy on clinical response to certolizumab pegol maintenance therapy for Crohn's disease. Aliment Pharmacol Ther. 2010;32(3):384-393.
  5. Lichtenstein GR, Thomsen OO, Schreiber S, et al. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. Clin Gastroenterol Hepatol. 2010;8(7):600-609.
  6. Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007;13(11):1323-1332.
  7. Palframan R, Airey M, Moore A, Vugler A, Nesbitt A. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods. 2009;348(1-2):36-41.
  8. Rutgeerts P, Schreiber S, Feagan B., Keininger DL, O'Neil L, Fedorak RN. Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn's disease. Int J Colorectal Dis. 2008;23(3):289-296.
  9. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007;357(3):228-238.
  10. Sandborn WJ, Vermeire S, D'Haens G, et al. WELCOME: A randomized, double-blind, controlled trial comparing certolizumab pegol 400 mg every 2 weeks with every 4 weeks for maintenance of response and remission in patients with moderate-to-severe Crohn's disease with secondary failure to infliximab. Paper presented at: 4th Congress of ECCO; February 5-7 2009; Hamburg, Germany. J Crohns Colitis. 2009;3(1):S8-S9.
  11. Sandborn WJ, Abreu MT, D'Haens G, et al. Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease and Secondary Failure to Infliximab. Clin Gastroenterol Hepatol. 2010;8(8):688-695.e2. 2010 May 6.
  12. Sandborn WJ, Schreiber S, Hanauer SB, Colombel JF, Bloomfield R, Lichtenstein GR. Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 study. Clin Gastroenterol Hepatol. 2010;8(8):696-702. 2010 Apr 2.
  13. Schreiber S, Rutgeerts P, Fedorak RN, et al. Erratum: A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology. 2005;129(5):1808.
  14. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007;357(3):239-250.
  15. Schreiber S, Colombel JF, Bloomfield R, et al. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol. 2010;105(7):1574-1582.
  16. Vermeire S, D'Haens G, Colombel JF, et al. Efficacy of certolizumab pegol is not affected by baseline anti-infliximab antibody status in patients with Crohn's disease with secondary infliximab failure. Inflamm Bowel Dis. 2009;15(Suppl 2):S13-S14. Abstract presented at: Advances in Inflammatory Bowel Diseases, CCFA (Crohn's and Colitis Foundation of America) National Clinical & Research Conference; December 3-6, 2009; Hollywood, FL.